Page last updated: 2024-10-23
bumetanide and Chronic Kidney Diseases
bumetanide has been researched along with Chronic Kidney Diseases in 1 studies
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "In CKD stage 4-5 KDIGO without renal replacement therapy, bumetanide in combination with chlorthalidone is more effective in treating volume overload and hypertension than bumetanide with placebo." | 9.51 | Effect of the combination of bumetanide plus chlorthalidone on hypertension and volume overload in patients with chronic kidney disease stage 4-5 KDIGO without renal replacement therapy: a double-blind randomized HEBE-CKD trial. ( Cabrera-Barron, R; Chida-Romero, JA; Dehesa-López, E; Madero, M; Martin-Alemañy, G; Perez-Navarro, LM; Solis-Jimenez, F; Valdez-Ortiz, R, 2022) |
| "In CKD stage 4-5 KDIGO without renal replacement therapy, bumetanide in combination with chlorthalidone is more effective in treating volume overload and hypertension than bumetanide with placebo." | 5.51 | Effect of the combination of bumetanide plus chlorthalidone on hypertension and volume overload in patients with chronic kidney disease stage 4-5 KDIGO without renal replacement therapy: a double-blind randomized HEBE-CKD trial. ( Cabrera-Barron, R; Chida-Romero, JA; Dehesa-López, E; Madero, M; Martin-Alemañy, G; Perez-Navarro, LM; Solis-Jimenez, F; Valdez-Ortiz, R, 2022) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Solis-Jimenez, F | 1 |
| Perez-Navarro, LM | 1 |
| Cabrera-Barron, R | 1 |
| Chida-Romero, JA | 1 |
| Martin-Alemañy, G | 1 |
| Dehesa-López, E | 1 |
| Madero, M | 1 |
| Valdez-Ortiz, R | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| Chlortalidone and Bumetanide in Advanced Chronic Kidney Disease: HEBE-CKD Trial[NCT03923933] | Phase 2 | 34 participants (Actual) | Interventional | 2019-06-18 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Change in Diastolic Blood Pressure
(NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | mmHg (Mean) |
|---|
| Placebo | -3.4 |
| Treatment Grup | -13.5 |
Change in Extracellular Water
Decrease in extracellular water measured by bioelectrical impedance analysis (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | litres (Mean) |
|---|
| Placebo | -0.15 |
| Treatment Grup | 2.55 |
Change in Extracellular Water / Total Body Water Ratio
Decrease in extracellular water / total body water ratio measured by bioelectrical impedance analysis (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | percentage of ECW/TBW (Mean) |
|---|
| Placebo | -0.24 |
| Treatment Grup | -2.92 |
Change in Mean Arterial Pressure
decrease in blood pressure compared wit baseline measure (mmhg) (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | mmHg (Mean) |
|---|
| Placebo | -5.4 |
| Treatment Grup | -18.1 |
Change in Systolic Blood Pressure
(NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | mmHg (Mean) |
|---|
| Placebo | -10 |
| Treatment Grup | -26.1 |
Change in the Fractional Excretion of Sodium
Increase in the fractional excretion of sodium compared with the baseline measure (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | percentage of sodium excreted (Mean) |
|---|
| Placebo | -0.348 |
| Treatment Grup | 0.598 |
Change in Total Body Water
Measured by bioelectrical impedance analysis, compared to the initial measurement (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | litres (Mean) |
|---|
| Placebo | -0.075 |
| Treatment Grup | -4.36 |
Trials
1 trial available for bumetanide and Chronic Kidney Diseases